Skip to content

Rhinovirus Study With Lactobacillus Rhamnosus GG

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01229917
Enrollment
Unknown
Registered
2010-10-28
Start date
Unknown
Completion date
Unknown
Last updated
2011-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Tract Infections [C08.730]

Brief summary

The purpose of this study is to evaluate the symptom impact of probiotic Lactobacillus rhamnosus GG during rhinovirus infection.

Interventions

OTHERFruit juice with Lactobacillus rhamnosus GG, version 1
OTHERFruit juice with Lactobacillus rhamnosus GG, version 2
OTHERStandard fruit juice

Sponsors

University of Helsinki
CollaboratorOTHER
University of Virginia
CollaboratorOTHER
Medcare Ltd
CollaboratorUNKNOWN
Valio Ltd
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Male or female in general good health (stabilized chronic illnesses and regular medications are accepted, if not otherwise mentioned in the

Exclusion criteria

) 2. Age 18-65 years 3. Serum neutralizing antibody titer of 1:4 or less for the challenge rhinovirus 4. No clinically significant finding on the pre-study nasal examination 5. Females must have a negative urine pregnancy test, and women of child-bearing potential must be using an effective method of birth control such as, but not limited to birth control pills, contraceptive foam, diaphragm, IUD, surgical sterilization, abstinence, or condoms 6. Written informed consent must be obtained at enrollment into the study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026